FDA backs pediatric warnings on Zyprexa, Lamisil

In advance of tomorrow's pediatric advisory committee meeting at the FDA, agency staffers are recommending new cautionary language for Eli Lilly's antipsychotic Zyprexa (about the risks of weight gain and diabetes in children) and Novartis' antifungal Lamisil (about the risk of psychiatric side effects, also in children). Report

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.